Leerink Partners Maintains Outperform on Boston Scientific, Lowers Price Target to $50
Leerink Partners analyst Mike Kratky maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $55 to $50.
An expert analyst still likes Boston Scientific but thinks the stock might be worth less money soon. This means the company is probably still doing okay, but people might not pay as much for it right now.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.